Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail...
-
Upload
milton-henry -
Category
Documents
-
view
215 -
download
1
Transcript of Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail...
![Page 1: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/1.jpg)
Bringing Evidence-Based Medicine to Consumers
Alliance for Health Reform
January 12, 2005
Gail Shearer
Director, Health Policy Analysis
Washington Office
Consumers Union
![Page 2: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/2.jpg)
“Consumer Driven” Health Care?• Is it defined contribution health care in reality?• Adverse segmentation of the health insurance
marketplace• Evidence-based medicine should be foundation
for universal coverage, comprehensive drug benefits, and improvements in the marketplace as it saves money and rationalizes delivery of care
![Page 3: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/3.jpg)
Section 1013: Medicare Modernization Act• Bipartisan effort• Appeals to those who want to provide financial
relief• Appeals to those who want to curb federal
spending and deficit• AHRQ priorities: constructive first step• Section 1013 calls for findings that are “easily
understood” by the public and available both online and in print
![Page 4: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/4.jpg)
MISSION:
• Information on prescription drugs for consumers and doctors
• Increase access to and affordability of needed medicines
• Relieve financial burden caused by high drug prices – consumers and businesses
![Page 5: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/5.jpg)
METHODS: (1) Drug Effectiveness Review Project
• Pioneering work under leadership of former Oregon Governor John Kitzhaber
• Partnership (DERP) now includes 12 states and two non-profit organizations
• Systematic reviews by AHRQ’s Evidence-Based Practice Centers
• Process: transparent, unbiased, rigorous, highly regarded
![Page 6: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/6.jpg)
METHODS: (2) Medical Input and Prices
• Input from medical consultant• Data on average national retail price paid by
cash-paying consumer• CU team reviews effectiveness and cost• Input from CU’s medical advisor, health editorial
team, statistician, 2-3 outside medical peer reviewers for each category
![Page 7: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/7.jpg)
METHODS: (3) Identifying CR Best Buy Drugs
CU team reviews the effectiveness and cost data, and selects one or more drugs that:
• Are in the top tier of effectiveness• Have a safety record as good as others in the
category• Have an average price substantially lower than
the most costly drug in the category
![Page 8: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/8.jpg)
CR BEST BUY DRUGS: Cholesterol–Lowering Drugs/Statins
For moderate cholesterol reduction:
• Generic lovastatin
Substantial cholesterol reduction:
• Atorvastatin (Lipitor)
![Page 9: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/9.jpg)
POSSIBLE ANNUAL SAVINGS: 3 Categories
• Statins $1,300 (cholesterol)
• Proton Pump Inhibitors: $1,740 (acid reflux and ulcers)
• NSAIDs $2,200 (arthritis and pain)
![Page 10: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/10.jpg)
Just the beginning …
• Continue to draw on DERP reports
• One per month
• Next up: anti-depressants (SSRIs), high blood pressure and heart disease (ACE Inhibitors and Beta Blockers)
![Page 11: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/11.jpg)
![Page 12: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/12.jpg)
![Page 13: Bringing Evidence-Based Medicine to Consumers Alliance for Health Reform January 12, 2005 Gail Shearer Director, Health Policy Analysis Washington Office.](https://reader035.fdocuments.us/reader035/viewer/2022062517/56649f135503460f94c27380/html5/thumbnails/13.jpg)